Inotiv Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 146/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.83.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Inotiv Inc's Score
Industry at a Glance
Industry Ranking
146 / 404
Overall Ranking
270 / 4582
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
3
analysts
Buy
Current Rating
4.833
Target Price
+482.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Inotiv Inc Highlights
StrengthsRisks
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Overvalued
The company’s latest PE is -0.32, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.82M shares, decreasing 27.89% quarter-over-quarter.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Ticker SymbolNOTV
CompanyInotiv Inc
CEOLeasure (Robert W)
Websitehttps://www.inotiv.com/
FAQs
What is the current price of Inotiv Inc (NOTV)?
The current price of Inotiv Inc (NOTV) is 0.668.
What is the symbol of Inotiv Inc?
The ticker symbol of Inotiv Inc is NOTV.
What is the 52-week high of Inotiv Inc?
The 52-week high of Inotiv Inc is 5.670.
What is the 52-week low of Inotiv Inc?
The 52-week low of Inotiv Inc is 0.610.
What is the market capitalization of Inotiv Inc?
The market capitalization of Inotiv Inc is 22.95M.
What is the net income of Inotiv Inc?
The net income of Inotiv Inc is -68.63M.
Is Inotiv Inc (NOTV) currently rated as Buy, Hold, or Sell?
According to analysts, Inotiv Inc (NOTV) has an overall rating of Buy, with a price target of 4.833.
What is the Earnings Per Share (EPS TTM) of Inotiv Inc (NOTV)?
The Earnings Per Share (EPS TTM) of Inotiv Inc (NOTV) is -2.115.